[HTML][HTML] Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents
LM Wise, W Stohl - Frontiers in Medicine, 2020 - frontiersin.org
Given the centrality of B cells to systemic lupus erythematosus (SLE), it stands to reason that
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …
[HTML][HTML] Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
LM Wise, W Stohl - Frontiers in Medicine, 2020 - ncbi.nlm.nih.gov
Given the centrality of B cells to systemic lupus erythematosus (SLE), it stands to reason that
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …
Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
LM Wise, W Stohl - Frontiers in medicine, 2020 - pubmed.ncbi.nlm.nih.gov
Given the centrality of B cells to systemic lupus erythematosus (SLE), it stands to reason that
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …
[引用][C] Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
LM Wise, W Stohl - Frontiers in Medicine (Web), 2020 - jglobal.jst.go.jp
Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting
Agents | Article Information | J-GLOBAL Art J-GLOBAL ID:202002285858218564 Reference …
Agents | Article Information | J-GLOBAL Art J-GLOBAL ID:202002285858218564 Reference …
Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents.
LM Wise, W Stohl - Frontiers in Medicine, 2020 - europepmc.org
Given the centrality of B cells to systemic lupus erythematosus (SLE), it stands to reason that
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …
Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents.
LM Wise, W Stohl - Frontiers in Medicine, 2020 - europepmc.org
Given the centrality of B cells to systemic lupus erythematosus (SLE), it stands to reason that
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …